Zanidatamab is a monoclonal antibody commercialized by Jazz Pharmaceuticals, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 16 clinical trials, of which 11 are ongoing, and 5 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zanidatamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Zanidatamab is expected to reach an annual total of $284 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Zanidatamab is under development for the treatment of HER2-expressing cancers such as salivary gland cancer, endometrial cancer, biliary tract cancer, fallopian tube cancer, cervical cancer, gall bladder cancer, cholangiocarcinoma, bile duct cancer (cholangiocarcinoma), metastatic breast cancer (HER2-positive and HR positive), metastatic ovarian cancer, non-small cell lung cancer, gastric and gastroesophageal junction carcinomas, gastroesophageal junction, adenocarcinoma of the gastroesophageal junction, esophageal adenocarcinomas and metastatic colorectal cancer. It is administered intravenously. ZW-25 is a humanized bi-specific monoclonal antibody targeting the extracellular domain of HER2. The drug candidate is based on Azymetric technology.
It was also under development for adnexal carcinoma of skin.
Jazz Pharmaceuticals Overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Erwinaze (asparaginase erwinia chrysanthemi), Defitelio (defibrotide sodium), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
The company reported revenues of (US Dollars) US$3,659.4 million for the fiscal year ended December 2022 (FY2022), an increase of 18.3% over FY2021. The operating loss of the company was US$65.5 million in FY2022, compared to an operating profit of US$170.3 million in FY2021. The net loss of the company was US$224.1 million in FY2022, compared to a net loss of US$329.7 million in FY2021. The company reported revenues of US$892.8 million for the first quarter ended March 2023, a decrease of 8.2% over the previous quarter.
For a complete picture of Zanidatamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.